FLX Bio, Inc. is an immuno-oncology company focused on the discovery and development of orally-available, small molecule drugs to activate the immune system and eradicate cancer. Using its integrated immuno-oncology drug discovery platform, FLX Bio's small molecule compounds specifically target proteins and pathways important for regulatory T cells or myeloid cells within the tumor microenvironment.
Market
Cancer treatment
Location
San Francisco,
CA,
USA
Coinvestors
Celgene Corporation, The Column Group, Topspin Partners